|
U.S. Food and Drug Administration (FDA) has approved a new weight- loss drug manufactured by the pharmaceutical company Vivus.According to the BBC, the FDA approved the use of Qsymia for patients who are overweight or obese and have at least one other weight-related condition.he approval comes after the FDA gave another anti-obesity drug, Belviq, the green signal last month.The FDA said that two studies...
|
|
|
one-third of adults in the US are now obese, according to official figuresThe US Food and Drug Administration (FDA) has approved a new weight-loss drug from the pharmaceutical company Vivus.for patients who are overweight or obese and have at least one other weight-related condition.The approval comes after the FDA gave another anti-obesity drug, Belviq, the green light last month.The FDA said that...
|
|
|
as India is home to one of the highest populations of the visually impaired, eye health is the least priority for the population here, a global survey...
|
|
|
Qsymia, a combination of two drugs on the market to treat other conditions, is the second weight-loss pill approved within a month. A study will analyze the pill's possible health risks.Bottles of Qsymia, an anti-obesity drug, approved by the Food and Drug Administration for patients who are overweight or obese and also have at least one weight-related condition such as high blood pressure, diabetes...
|
|
|
|
|
product image provided by Vivus Pharmaceuticals Inc. shows bottles of Qsymia, the company's anti-obesity drug.The Food and Drug Administration on Tuesday approved a new weight loss drug from Vivus Inc. that many doctors consider the most effective therapy in a new generation of anti-obesity pills designed to help patients safely shed pounds.The agency cleared the pill Qsymia for adults who are obese...
|
|
|
drug regulators approved Vivus Inc's obesity drug late on Tuesday, the second new diet pill approved in the last month, as health advocates push for new solutions to combat obesity.Approval for the pill, to be sold under the brand name Qsymia, follows last month's go-ahead for Arena Pharmaceuticals' Belviq, but the approvals come after a 13-year dry spell for long-term weight loss drugs due to safety...
|
|
|
Food and Drug Administration approved Vivus Inc.'s weight-loss drug Qsymia Tuesday, marking the second approval of a new weight-loss drug in less than a month.In June, the agency approved a drug called Belviq, marketed by Arena Pharmaceuticals Inc. and distributed by Eisai Co. Ltd. The approval of both drugs had been held up for several years amid potential safety concerns that included heart-valve...
|
|
|
Shares of obesity drug developers Vivus Inc. and Orexigen Therapeutics Inc. rose Monday as regulators prepared to announce their decision on Vivus' experimental drug Qnexa.The Food and Drug Administration is scheduled to publish its decision on Qnexa by Tuesday. A panel of FDA advisers recommended in February that the drug be approved. The agency is not required to follow the advice of its panels,...
|
|
